Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q2 2013 Earnings Presentation

14 slides from Questcor Pharmaceuticals's earnings presentation, Aug 6, 2013

  1. Slide 1: Second Quarter 2013 Conference Call

    NASDAQ: QCOR Second Quarter 2013 Conference Call

  2. Slide 2: Conference Call Logistics

    Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: U.S.: (855) 859-2056. International: (404) 537-3406. Passcode: 16591264

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

  4. Slide 4: Q2-2013 Financial Highlights

    Q2-2013 Financial Highlights 7,050 vials shipped $184.6M GAAP net sales; $196.1M Non-GAAP net sales $1.12 GAAP diluted EPS; $1.35 Non-GAAP diluted EPS Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 12.

  5. Slide 5: Foundation for Growth

    Foundation for Growth Short-Term: Continue commercial pursuits in MS, NS, rheumatology and sarcoidosis. Investigate other on- label indications and build body of evidence. Mid-Term: Develop international market for Synacthen and develop it for U.S. market Longer-Term: New indications for Acthar, Syn

  6. Slide 6: New Paid Acthar Prescriptions by Therapeutic Area

    New Paid Acthar Prescriptions by Therapeutic Area* * Includes prescriptions covered by commercial carriers, Medicare, Medicaid and Tricare in all periods regardless of the rebate percentage applicable in those periods. Based on internal company estimates. Q2-2013 Q2-2012 Q1-2013 NS MS IS Rheumatolog

  7. Slide 7: Approximate Business Mix

    Approximate Business Mix Based on internal company estimates. Other 2% Rheumatology 18% Infantile Spasma 10% Neurology 30% Nephrology 40% Based on Acthar Net Sales

  8. Slide 8: Stable Reimbursement Environment

    Stable Reimbursement Environment MDs typically reserve Acthar for when another FDA- approved treatment alternative is needed, usually after first-line therapy Serious, difficult-to-treat medical conditions Coverage decisions are determined on a case-by-case basis, considering patient condition, dise

  9. Slide 9: The Emerging Science Behind Acthar and Synacthen

    The Emerging Science Behind Acthar and Synacthen Understanding the biological properties of Acthar and Synacthen Specific biochemical pathways, cells, and tissues Immunomodulation and anti-inflammatory effects Further research related to on-label indications Lupus Idiopathic Membranous Nephropathy N

  10. Slide 10: ALS Phase Open-Label Safety Study for Acthar

    ALS Phase 2 Open-Label Safety Study for Acthar Goals Assess short-term safety and tolerability of Acthar in ALS Inform dosage selection for future studies Study Design Enroll up to 40 patients at multiple sites in U.S. 8-week treatment, plus optional 28-week open label extension Patients randomized

  11. Slide 11: Q2-2013 Financial Results

    Q2-2013 Financial Results Q2-2013 Financial Results Net sales ($M) Net salses ($M), Non-GAAP fully Diluted, GAAP EPS Fully Diluted, Non-GAAP EPS Cash flow from operations ($M) Diluted shares outstanding Q2-2013 Q2-2012 Change $184.6 $196.1 $1.12 $1.35 $81.5 61.5 $112.5 $112.5 $0.65 $0.69 $43.2 64.1

  12. Slide 12: Reconciliation of Non-GAAP Adjusted Financial Disclosure

    Reconciliation of Non-GAAP Adjusted Financial Disclosure Net income per share – basic and diluted may not foot due to rounding. Net income per share – basic and diluted may not foot due to rounding. Use of Non-GAAP Financial Measures Our “non-GAAP adjusted net income” excludes the following items fr

  13. Slide 13: Q2-2013 Financial Highlights

    Q2-2013 Financial Highlights ,050 vials shipped $184.6M GAAP net sales; $196.1M Non-GAAP net sales $1.12 GAAP diluted EPS; $1.35 Non-GAAP diluted EPS Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 12.

  14. Slide 14: Second Quarter 2013 Conference Call

    Second Quarter 2013 Conference Call NASDAQ: QCOR

Questcor Pharmaceuticals — Q2 2013 Earnings Presentation on 6ix